Post hoc analysis of a randomized, double-blind, prospective trial evaluating a CXCR1/2 inhibitor in new-onset type 1 diabetes: endo-metabolic features at baseline identify a subgroup of responders

Valeria Sordi, Paolo Monti, Vito Lampasona, Raffaella Melzi, Silvia Pellegrini, Bart Keymeulen, Pieter Gillard, Thomas Linn, Emanuele Bosi, Ludger Rose, Paolo Pozzilli, Francesco Giorgino, Efisio Cossu, Lorenzo Piemonti

Research output: Contribution to journalArticlepeer-review

7 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Post hoc analysis of a randomized, double-blind, prospective trial evaluating a CXCR1/2 inhibitor in new-onset type 1 diabetes: endo-metabolic features at baseline identify a subgroup of responders'. Together they form a unique fingerprint.

Medicine & Life Sciences